Physicians' Academy for Cardiovascular Education

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

CSI Rome Terje Pedersen (Oslo, Norway) defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans (both UMC Utrecht, The Netherlands) that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.

Educational information

In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.

The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in the session on PCSK9 inhibitors in the Gladiators Arena at the ESC Congress 2016, with speakers in this session.

Faculty & Disclosures

Terje Rolf Pedersen - Professor Emeritus - Department of Endocrinology, Morbid Obesity and Preventive Medicine, UiO Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway

Lotte Koopal and Gijs Berkelmans - UMC Utrecht, The Netherlands

The speakers did not receive financial compensation for participating in these interviews